Penumbra with ticker code (PEN) now have 6 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 350 and 300 with the average target price sitting at 323.17. With the stocks previous close at 201.43 this would indicate that there is a potential upside of 60.4%. There is a 50 day moving average of 223.37 and the 200 moving average now moves to 256.85. The company has a market cap of $7,866m. Visit the company website at: https://www.penumbra.com
The potential market cap would be $12,620m based on the market concensus.
Penumbra designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, luding revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra was founded in 2004 and is headquartered in Alameda, California.
